Advanced breast cancer (ABC) is considered to include both locally advanced and stage IV (metastatic) cancer, and the median survival of patients with ABC is just 2-3 years. Despite the availability of various treatment options, the major clinical challenges in the diagnosis and treatment of breast cancer are recurrence and the incurability of the advanced disease. 1 Ribociclib in combination with aromatase inhibitors significantly prolonged progression-free survival in patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. 2 References Büyükkaramikli NC, et al., PharmacoEconomics. 2019 Feb 13;37(2):141-53.
Hortobagyi GN, et al., New England Journal of Medicine. 2016 Nov 3;375(18):1738-48. Novartis and Docplexus have organized an Interactive Webinar on 15 th October 2020 from 05:30 pm onwards. In this webinar, Dr. Govind…
